

QUICK FACTS:

Company Founded:	1981
Corporate Headquarters:	Danvers, Massachusetts
European Division:	Aachen and Berlin, Germany; Tokyo, Japan
CEO, Chairman and President:	Michael R. Minogue
NASDAQ:	ABMD



Manufactures Impella®, the world's smallest heart pump.



Developed AbioCor™, the First Total Artificial Heart.

OUR PRODUCTS: IMPELLA®, THE WORLD'S SMALLEST HEART PUMP

The Impella portfolio includes Impella 2.5®, Impella CP®, Impella 5.0®, Impella LD® and Impella RP®.

- Impella devices temporarily assist the pumping function of the heart and provide blood supply to vital organs, enabling the heart muscle to rest and potentially recover.
- Impella devices are smaller than the width of a pencil and can be inserted using a minimally-invasive catheterization technique.
- Impella heart pumps have the unique ability to enable heart recovery, allowing patients to return home with their native heart. Heart recovery is the ideal option for quality of life and has the ability to save costs for the healthcare system^{1,2,3}.

PROTECTED PCI WITH IMPELLA 2.5® AND IMPELLA CP®

Protected PCI (percutaneous coronary intervention) procedures are often performed on patients who are turned down for surgery or told that they have no other options to treat their heart failure.

- The Impella 2.5® and Impella CP® are the only Food & Drug Administration (FDA) approved percutaneous hemodynamic support devices determined to be safe and effective for the treatment of certain elective and urgent high risk advanced heart failure patients.
- For patients with advanced heart failure, Impella heart pumps can be used in minimally-invasive Protected PCI procedures to allow the heart to rest while physicians perform procedures, such as stenting or angioplasty, to unblock arteries and restore blood flow.

IMPELLA® THERAPY FOR CARDIOGENIC SHOCK

Cardiogenic shock typically occurs during or after a heart attack, when the heart suddenly cannot pump enough blood and oxygen to the body's vital organs.

- The Impella 2.5®, Impella CP®, Impella 5.0® and Impella LD® are the only minimally-invasive heart pumps determined safe and effective by the FDA to treat cardiogenic shock after a heart attack or open heart surgery.
- For patients in cardiogenic shock, the Impella heart pump assists the heart's pumping function, restoring blood flow to the body's vital organs. It allows the heart to rest and potentially recover.

IMPELLA RP® FOR THE RIGHT HEART FAILURE

Patients experiencing right ventricular failure may benefit from hemodynamic support.

- The Impella RP® is the only minimally-invasive, temporary ventricular support device that is FDA-approved as safe and effective to treat patients experiencing acute right heart failure or decompensation.
- For patients with right heart failure, the Impella RP® works to stabilize the patient's hemodynamics, unloads the right ventricle and allows for native heart recovery.

www.abiomed.com/Impella

To learn more about the Impella platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: www.impella.com/information/isi.

1. Maini B, Gregory D, Scotti DJ, Buyantseva L. Percutaneous cardiac assist devices compared with surgical hemodynamic support alternatives: Cost-Effectiveness in the Emergent Setting. *Catheter Cardiovasc Interv.* 2014 May 1;83(6):E183-92.
 2. Cheung A, Danter M, Gregory D. TCT-385 Comparative Economic Outcomes in Cardiogenic Shock Patients Managed with the Minimally Invasive Impella or Extracorporeal Life Support. *J Am Coll Cardiol.* 2012;60(17_5):. doi:10.1016/j.jacc.2012.08.413.
 3. Gregory D, Scotti DJ, de Lissovoy G, Palacios I, Dixon, Maini B, O'Neill W. A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention. *Am Health Drug Benefits.* 2013 Mar;6(2):88-99